Showing results (231-240 of 300) with videos related to

Sort By:
Pageof 30
NPJ Precision Oncology|September 12, 2024
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumorsJian Zhang, Yiqun Du, Yanchun Meng, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Future Oncology (London, England)|August 18, 2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III studyJin Li, Ruihua Xu, Shukui Qin, et al.
Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trialsJingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
Advances in Therapy|March 2, 2025
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 StudyShukui Qin, Yuxian Bai, Jin Li, et al.
Nature Communications|November 10, 2022
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junctionZhaoqing Tang, Yan Wang, Dan Liu, et al.
Cancer Science|January 17, 2019
Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinomaHaiyan Ma, Dan Yan, Yina Wang, et al.
Journal for Immunotherapy of Cancer|June 21, 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 studyLin Shen, Jun Guo, Qingyuan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
Pageof 30